drugset / Trial / NCT01602900

Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease

NCT01602900

Phase 1 Completed 8 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the amount of drug in the blood. The study will involve healthy male volunteers.

Timeline

Start
2011-11-22
Primary completion
2012-04-12
Completion
2012-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK356278 Small molecule Oral
Background Rolipram Diagnostic / imaging agent

Indications